Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 2
2018 12
2019 14
2020 26
2021 42
2022 11
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 35220243

99 results

Results by year

Filters applied: . Clear all
Page 1
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Tawbi HA, et al. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. N Engl J Med. 2022. PMID: 34986285 Free PMC article. Clinical Trial.
A real-world data of Immune checkpoint inhibitors in solid tumors from India.
Noronha V, Abraham G, Patil V, Joshi A, Menon N, Mahajan A, Janu A, Jain S, Talreja VT, Kapoor A, Kumar Singh G, Khaddar S, Gupta K, Rathinasamy N, Srinivas S, Agrawal A, Ventrapati P, Prabhash K. Noronha V, et al. Cancer Med. 2021 Mar;10(5):1525-1534. doi: 10.1002/cam4.3617. Epub 2021 Feb 16. Cancer Med. 2021. PMID: 33591635 Free PMC article.
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguet AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, De Ruysscher D. Peters S, et al. Lung Cancer. 2019 Jul;133:83-87. doi: 10.1016/j.lungcan.2019.05.001. Epub 2019 May 3. Lung Cancer. 2019. PMID: 31200833 Clinical Trial.
Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.
Ishi A, Tanaka I, Iwama S, Sakakibara T, Mastui T, Kobayashi T, Hase T, Morise M, Sato M, Arima H, Hashimoto N. Ishi A, et al. Endocr J. 2021 May 28;68(5):613-620. doi: 10.1507/endocrj.EJ20-0769. Epub 2021 May 1. Endocr J. 2021. PMID: 33790087 Free article.
99 results